Skin Transplantation Clinical Trial
Official title:
Clinical Randomized Controlled Trials on Negative Pressure Wound Therapy for Skin Grafts
NCT number | NCT02374528 |
Other study ID # | 2015046 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 2015 |
Est. completion date | December 2018 |
Verified date | February 2019 |
Source | First Affiliated Hospital, Sun Yat-Sen University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The repairing of various wounds is always a great challenge in burn surgery and plastic surgery. Skin-grafting is the main therapy. Bolster dressings are traditionally applied to secure the graft to the wound bed, however, there is some evidence to show that irregularly contoured recipient sites, poorly healing areas, reduce the success rate of skin-grafting with traditional bolster dressings, increasing morbidity, pain. Negative pressure wound therapy has been advocated as a potential solution to some of these issues. To further test the healing rate and safety of this new method, the investigators propose a prospective randomized controlled trial to compare this method with traditional bolster dressings application in skin-grafting.
Status | Completed |
Enrollment | 98 |
Est. completion date | December 2018 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 85 Years |
Eligibility |
Inclusion Criteria: - Subjects who need to skin graft to repair the wound - Subjects signed the informed consent in the day of the age of not more than 85 years old (for minors, legal guardian should be signed) - Stable vital signs, regular examination showed that subjects could tolerate surgery - Subjects' mental state are good, could follow the doctor's advice, visit on a regular basis - Understanding and willing to participate in this clinical trial and signed informed consent - All women subjects must agree to take effective contraceptive measures in the six months study period, and without pregnancy before participate in the treatment - No other serious diseases conflicts with the trail Exclusion Criteria: - Allergic constitution of negative pressure dressing - Severe uncontrolled disease or acute systemic infections and complication with other serious heart, lung disease, encephalopathy and other organs or have a rapid progress or terminal disease - Subjects with mental illness - Subjects could not cooperate with the clinical trial personnel to finish trials - Existing disease (malignant tumor, autoimmune disease) or require the use of drugs (high-dose glucocorticoids, which is defined as accepting 40 mg or more daily prednisone or prednisone amount, period of two weeks or more) will affect the healing of the wound - For HIV positive patients, clinical diagnosis of patients with AIDS or the screening phase of neutrophil count (ANC) absolutely < 1000 cells/mm3 - Subjects could not tolerate surgery - Subjects are unlikely to survive in the study period - The investigators think that who should not be included - Subjects are in or participated in other clinical researchers over the past 12 weeks - Subjects are participated in this trial at any time in the past |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital, Sun Yat-Sen University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | healing rate (the percentage of subjects that achieved complete wound closure, complete wound closure is defined as skin complete reepithelialization without drainage or dressing requirements) | the percentage of subjects that achieved complete wound closure, complete wound closure is defined as skin complete reepithelialization without drainage or dressing requirements. | postsurgery week 4 | |
Secondary | VAS pain grade | assess the pain of the wound at each visit time | postsurgery week 4 | |
Secondary | Skin graft survival rate | The area of the skin graft has been survival percentage accounted for the entire | postsurgery week 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00362219 -
Topical Morphine for Analgesia in Patients With Skin Grafts
|
Phase 3 | |
Not yet recruiting |
NCT05666999 -
Post-market Clinical Follow-up Study for a CE Marked Wound Care Product (FibDex®)
|
N/A | |
Recruiting |
NCT06255990 -
Clinical and Histological Study of a Novel Dermal Substitute
|
||
Completed |
NCT03980600 -
NFC Dressing for Skin Graft Donor Sites
|
N/A | |
Enrolling by invitation |
NCT01133145 -
Allogeneic Vascularized Knee Transplantation
|
N/A |